Welcome to the thread Immunityman, aka Oliver and Co.! A prescribing physician at an AIDS clinic will be a valuable asset to the thread, and something I don't believe we've benefited from before.
I agree; if we don't get a spike back up in the stock price tomorrow, I too will be buying calls on margin. I must admit, this is getting old, and expensive. If the stock starts back up, then the house may get paid off extra early! If south, then, hoo-boy, I'll be rolling 'em down. Still, we have 2 months to go for the Nov expirations. Any gutsy guys or gals out there snapping up very cheap October calls, looking for a quick, high risk buck?
BTW, I've never disclosed my backround, but I'm a chemical researcher in the pharma industry. I do organic synthesis on developmental drugs the company intends to take into the clinic. Been at it 10 years. Thus I have significant passing knowledge about drug development, some understanding of clinical trials, and some limited regulatory experience at the IND stage, but not NDA. Will try to field questions as they pertain to AGPH/Viracept/Thymitaq, etc.
Welcome again. Question to you: Can you offer any comparison between the various drug reps - how do AGPH's compare with Merck's, Abbotts, Roche's, etc.
TIA,
Randy |
